Prophylactic or Preemptive Infusion Of Donor-Derived CD19 CAR-T Cell Therapy in High-Risk B-Cell Acute Lymphoblastic Leukaemia Following Allogeneic Transplantation: A Post-Hoc Analysis of Two Clinical Trials
Wenyi Lu(Tianjin First Center Hospital), Mingfeng Zhao(Nankai University), Xin Jin(Nankai University), Xue Bai(Southwest Medical University), Hairong Lyu(Tianjin First Center Hospital), Haibo Zhu(Tianjin First Center Hospital), Tianle Xie(Nankai University), Bing Wang(Southwest University of Science and Technology), Meng Zhang(Nankai University), Jiaxi Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Hongkai Zhang(Nankai University), Xia Xiao(Hebei Medical University), Zhao Wang(Nankai University), Xinping Cao(Sun Yat-sen University), Rui Sun(Tianjin Medical University Eye Hospital), Juanxia Meng(Nankai University), Haotian Meng(University of Jinan), Yedi Pu(Tianjin First Center Hospital), Ting Yuan(China Pharmaceutical University), Xiaomei Zhang(Tang Hospital), Yuxin An(Tianjin Medical University)
Cited by 0
Related Papers
Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages
|Theranostics|2020|397
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia
|Journal of Hematology & Oncology|2022|149